CN117625543A - 工程化Th9细胞及其用途 - Google Patents
工程化Th9细胞及其用途 Download PDFInfo
- Publication number
- CN117625543A CN117625543A CN202211010624.2A CN202211010624A CN117625543A CN 117625543 A CN117625543 A CN 117625543A CN 202211010624 A CN202211010624 A CN 202211010624A CN 117625543 A CN117625543 A CN 117625543A
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- hla
- combination
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 79
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 230000011664 signaling Effects 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 230000000139 costimulatory effect Effects 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- -1 LIGHT Proteins 0.000 claims description 12
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 108010002586 Interleukin-7 Proteins 0.000 claims description 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 8
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims description 8
- 102100021592 Interleukin-7 Human genes 0.000 claims description 8
- 102100035304 Lymphotactin Human genes 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 102000002029 Claudin Human genes 0.000 claims description 7
- 108050009302 Claudin Proteins 0.000 claims description 7
- 102100035298 Cytokine SCM-1 beta Human genes 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 101000804771 Homo sapiens Cytokine SCM-1 beta Proteins 0.000 claims description 7
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 5
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 4
- 102100020986 DNA-binding protein RFX5 Human genes 0.000 claims description 4
- 102100021044 DNA-binding protein RFXANK Human genes 0.000 claims description 4
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 4
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 4
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 4
- 101100382122 Homo sapiens CIITA gene Proteins 0.000 claims description 4
- 101001075432 Homo sapiens DNA-binding protein RFX5 Proteins 0.000 claims description 4
- 101001075464 Homo sapiens DNA-binding protein RFXANK Proteins 0.000 claims description 4
- 101001075466 Homo sapiens Regulatory factor X-associated protein Proteins 0.000 claims description 4
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100026371 MHC class II transactivator Human genes 0.000 claims description 4
- 108700002010 MHC class II transactivator Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 102100021043 Regulatory factor X-associated protein Human genes 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000007910 cell fusion Effects 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 3
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 102100021317 Inducible T-cell costimulator Human genes 0.000 claims description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims description 2
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 102100037904 CD9 antigen Human genes 0.000 claims description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims description 2
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 2
- 108010041384 HLA-DPA antigen Proteins 0.000 claims description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 claims description 2
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 claims description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 2
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 claims description 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 2
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 2
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 claims description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 2
- 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 2
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 claims 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims 1
- 102100026894 Lymphotoxin-beta Human genes 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 101000864964 Rattus norvegicus Septin-9 Proteins 0.000 claims 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- 230000027455 binding Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 11
- 210000002865 immune cell Anatomy 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 230000030279 gene silencing Effects 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 102000000585 Interleukin-9 Human genes 0.000 description 5
- 108010002335 Interleukin-9 Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 210000003236 esophagogastric junction Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 101150076359 Mhc gene Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102100024263 CD160 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100026549 Caspase-10 Human genes 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100038918 Caspase-6 Human genes 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 101150075117 Ccl12 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101000809594 Escherichia coli (strain K12) Shikimate kinase 1 Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100040754 Guanylate cyclase soluble subunit alpha-1 Human genes 0.000 description 1
- 102100040735 Guanylate cyclase soluble subunit alpha-2 Human genes 0.000 description 1
- 102100040739 Guanylate cyclase soluble subunit beta-1 Human genes 0.000 description 1
- 102100028963 Guanylate cyclase soluble subunit beta-2 Human genes 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 102100028008 Heme oxygenase 2 Human genes 0.000 description 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 description 1
- 102100030234 Homeobox protein cut-like 1 Human genes 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 1
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 1
- 101000859758 Homo sapiens Cartilage-associated protein Proteins 0.000 description 1
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 description 1
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 description 1
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 1
- 101000916686 Homo sapiens Cytohesin-interacting protein Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101001038755 Homo sapiens Guanylate cyclase soluble subunit alpha-1 Proteins 0.000 description 1
- 101001038749 Homo sapiens Guanylate cyclase soluble subunit alpha-2 Proteins 0.000 description 1
- 101001038731 Homo sapiens Guanylate cyclase soluble subunit beta-1 Proteins 0.000 description 1
- 101001059095 Homo sapiens Guanylate cyclase soluble subunit beta-2 Proteins 0.000 description 1
- 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101001083151 Homo sapiens Interleukin-10 receptor subunit alpha Proteins 0.000 description 1
- 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 description 1
- 101001068019 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Proteins 0.000 description 1
- 101000863692 Homo sapiens Ski oncogene Proteins 0.000 description 1
- 101000688996 Homo sapiens Ski-like protein Proteins 0.000 description 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 1
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 description 1
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 101000761459 Mesocricetus auratus Calcium-dependent serine proteinase Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 1
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100034470 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Human genes 0.000 description 1
- 102100029969 Ski oncogene Human genes 0.000 description 1
- 102100024451 Ski-like protein Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 108091007178 TNFRSF10A Proteins 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- BSZPYRJQDZNENV-UHFFFAOYSA-N [Na].c1cc2cc3ccc(cc4ccc(cc5ccc(cc1n2)[nH]5)n4)[nH]3 Chemical compound [Na].c1cc2cc3ccc(cc4ccc(cc5ccc(cc1n2)[nH]5)n4)[nH]3 BSZPYRJQDZNENV-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 description 1
- 229940125666 actinium-225 Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- JCXGWMGPZLAOME-OUBTZVSYSA-N bismuth-210 Chemical compound [210Bi] JCXGWMGPZLAOME-OUBTZVSYSA-N 0.000 description 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本公开提供用于癌症疗法的工程化Th9细胞以及包含其的组合物。
Description
技术领域
本公开属于免疫治疗领域。更具体地,本公开涉及一种用于癌症疗法的工程化Th9细胞以及包含其的组合物。
背景技术
近年来,细胞治疗作为一种新兴的肿瘤治疗手段,已经在临床中展现出非常显著的疗效。细胞治疗主要是对免疫细胞进行体外扩增,然后再回输给肿瘤患者,以达到治疗目的。然而,这种疗法仍然面临细胞耗竭较快,在患者体内持续性不够等问题,导致疗效下降。因此,如何提高免疫细胞的持续性是该领域长期面临的挑战之一。
本公开通过筛选特定的免疫细胞亚型,并表达特定的细胞因子,能够降低免疫细胞的耗竭,进而提高其肿瘤抑制效果。
发明内容
除非另有说明,否则本文中所使用的所有科学技术术语的含义与本公开所属领域的普通技术人员通常所了解的相同。
本公开的目的在于提供一种工程化的Th9细胞,其表达特异性识别Claudin18.2的细胞表面分子,例如TCR、CAR等。与常规CAR-T细胞相比,该工程化的Th9细胞耗竭速度更低,扩增能力更强,具有更好的肿瘤抑制效果。
工程化的Th9细胞
在第一个方面,本公开提供一种工程化的Th9细胞,其表达特异性识别Claudin18.2的细胞表面分子。
Th9细胞于2008年首次被发现,属于CD4+T细胞的一种新亚型,其特征在于能够分泌IL-9。目前,Th9细胞与肿瘤的关系还不明确,一方面IL-9表达失调会导致某些自主细胞增殖和淋巴细胞的恶性转化,对肿瘤生长起促进作用。另一方面,Th9细胞最近也被证实具有抗肿瘤作用。Th9细胞这种在肿瘤中的双重作用可能与肿瘤类型及局部肿瘤微环境的差异有关。本公开首次发现,用Th9细胞代替传统的T细胞(即,未经分选的含有各种亚群(例如CD4+T细胞和CD8+T细胞)的T细胞)来构建靶向Claudin18.2的CAR-T细胞,在体外杀伤和小鼠模型方面,均显示出强烈的肿瘤杀伤活性。
在一个实施方案中,细胞表面分子选自嵌合抗原受体、T细胞受体、T细胞融合蛋白或T细胞抗原耦合器。如本文所用,术语“细胞表面分子”是指在细胞表面表达的能够与Claudin18.2特异性结合的分子。此类表面分子一般包含能够与Claudin18.2特异性结合的抗原结合区、将表面分子锚定在细胞表面的跨膜结构域,以及负责信号传递的胞内结构域。常见的此类表面分子的实例包括例如T细胞受体(TCR)、嵌合抗原受体(CAR)、T细胞融合蛋白(TFP)或T细胞抗原耦合器(TAC)。
如本文所用,术语“T细胞受体”或“TCR”是T细胞表面的特征性标志,以非共价键与CD3结合形成复合物。抗原呈递细胞通过主要组织相容性复合体分子(MHC)将抗原肽呈递至T细胞并且结合至TCR复合物以诱发一系列胞内信号传导。TCR由分别形成异二聚体的六条肽链组成,其一般分为αβ型和γδ型。每条肽链包括恒定区和可变区,其中可变区负责结合特异性的抗原和MHC分子。
如本文所用,术语“嵌合抗原受体”或“CAR”是指人工构建的杂合多肽,该杂合多肽一般包括抗原结合区(例如抗体的抗原结合部分)、跨膜结构域和胞内结构域(包含共刺激结构域和/或初级信号传导结构域),各个结构域之间通过接头连接。CAR能够利用单克隆抗体的抗原结合特性以非MHC限制性的方式将T细胞和其它免疫细胞的特异性和反应性重定向至所选择的靶标。非MHC限制性的抗原识别给予CAR细胞与抗原处理无关的识别抗原的能力,因此绕过了肿瘤逃逸的主要机制。此外,当在T细胞内表达时,CAR有利地不与内源性T细胞受体(TCR)的α链和β链二聚化。
如本文所用,术语“T细胞融合蛋白”或“TFP”是指由TCR各组分衍生的重组多肽,通常由TCR亚基和与其连接的抗原结合区组成并在细胞表面表达。其中,TCR亚基包括至少部分TCR胞外结构域、跨膜结构域、TCR胞内信号结构域。
如本文所用,术语“T细胞抗原耦合器”或“TAC”包括三个功能结构域:1肿瘤靶向结构域,包括单链抗体、设计的锚蛋白重复蛋白(designed ankyrin repeat protein,DARPin)或其他靶向基团;2胞外区结构域,与CD3结合的单链抗体,从而使得TAC受体与TCR受体靠近;3跨膜区和CD4共受体的胞内区,其中,胞内区连接蛋白激酶LCK,催化TCR复合物的免疫受体酪氨酸活化基序(ITAM)磷酸化作为T细胞活化的初始步骤。
如本文所用,“抗原结合区”是指可以与抗原结合的任何结构或其功能性变体。抗原结合区可以是抗体结构,包括但不限于单克隆抗体、多克隆抗体、重组抗体、人抗体、人源化抗体、鼠源抗体、嵌合抗体及其功能性片段。例如,抗原结合区包括但不限于IgG、Fab、Fab'、F(ab')2、Fd、Fd′、Fv、scFv、sdFv、线性抗体、单域抗体、纳米抗体、双体、anticalin、DARPIN等,优选选自Fab、scFv、单域抗体和纳米抗体。在本公开中,抗原结合区可以是单价或二价,且可以是单特异性、双特异性或多特异性的抗体。
在一个实施方案中,所述细胞表面分子包含结合Claudin18.2的抗体。在一个实施方案中,所述抗体为完整抗体、Fab、Fab’、F(ab’)2、Fv片段、scFv抗体片段、线性抗体、sdAb或纳米抗体。优选地,所述抗体包含如SEQ ID NO:1、2、3所示的CDR-1、CDR-2和CDR-3。优选地,所述抗体与SEQ ID NO:4具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。
在一个实施方案中,所述细胞表面分子是包含结合Claudin18.2的抗体的嵌合抗原受体,所述嵌合抗原受体还包含跨膜结构域和胞内结构域,其中所述胞内结构域包含共刺激结构域和/或初级信号传导结构域。
如本文所用,术语“跨膜结构域”是指能够使嵌合抗原受体在免疫细胞(例如淋巴细胞、NK细胞或NKT细胞)表面上表达,并且引导免疫细胞针对靶细胞的细胞应答的多肽结构。跨膜结构域可以是天然或合成的,也可以源自任何膜结合蛋白或跨膜蛋白。当嵌合受体多肽与靶抗原结合时,跨膜结构域能够进行信号传导。特别适用于本公开中的跨膜结构域可以源自例如TCRα链、TCRβ链、TCRγ链、TCRδ链、CD3ζ亚基、CD3ε亚基、CD3γ亚基、CD3δ亚基、CD45、CD4、CD5、CD8α、CD9、CD16、CD22、CD33、CD28、CD37、CD64、CD80、CD86、CD134、CD137、CD154或它们的任意组合。优选地,所述跨膜结构域选自CD8α、CD4、CD28或CD278的跨膜结构域。更为优选地,所述跨膜结构域为CD8α或CD28跨膜结构域,与SEQ ID NO:5、6、7所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。
在一个实施方案中,本公开的嵌合抗原受体还可以包含位于抗体和跨膜结构域之间的铰链区。如本文所用,术语“铰链区”一般是指作用为连接跨膜结构域至抗原结合区的任何寡肽或多肽。具体地,铰链区用来为抗体提供更大的灵活性和可及性。铰链区可以包含最多达300个氨基酸,优选10至100个氨基酸并且最优选25至50个氨基酸。铰链区可以源自全部或部分的天然分子,如源自全部或部分的CD8、CD4或CD28的胞外区,或源自全部或部分的抗体恒定区。或者,铰链区可以是对应于天然存在的铰链序列的合成序列,或可以是完全合成的铰链序列。优选地,所述铰链区包含CD8α、CD28或I给G4的铰链区部分,与SEQ ID NO:17、18、19或20所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。
本公开的共刺激结构域可以是来自共刺激分子的细胞内功能性信号传导结构域,其可以包含所述共刺激分子的整个细胞内部分,或其功能片段。“共刺激分子”是指在T细胞上与共刺激配体特异性结合,由此介导T细胞的共刺激反应(例如增殖)的同源结合配偶体。共刺激分子包括但不限于1类MHC分子、BTLA和Toll配体受体。本公开的共刺激结构域的非限制性施例包括但不限于源自以下蛋白质的共刺激信号传导结构域:TLR9、TLR10、CARD11、CD2、CD7、CD8、CD18、CD27、CD28、CD30、CD40、CD54、CD83、CD134(OX40)、CD137(4-1BB)、CD270(HVEM)、CD272(BTLA)、CD276(B7-H3)、CD278(ICOS)、CD357(GITR)、DAP10、DAP12、LAT、NKG2C、SLP76、PD-1、LIGHT、TRIM、ZAP70或其任意组合。优选地,所述共刺激结构域选自4-1BB、CD28、CD27、OX40、CD278或其任意组合。更为优选地,所述共刺激结构域为4-1BB或CD28,与SEQ ID NO:8、9或10所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。
在一个实施方案中,本公开的嵌合抗原受体包含的初级信号传导结构域可以是T细胞受体和共受体的细胞质序列,其在抗原受体结合以后一同起作用以引发信号传导,以及这些序列的任何衍生物或变体和具有相同或相似功能的任何合成序列。初级信号传导结构域包含两种不同类型的细胞质信号序列:引发抗原依赖性初级活化的那些,以及以不依赖抗原的方式起作用以提供次级或共刺激信号的那些。初级细胞质信号序列可以包含许多免疫受体酪氨酸激活基序(ITAM)。本公开的初级信号传导结构域包括单不限于源自FcRγ、FcRβ、CD3γ、CD3δ、CD3ε、CD3ζ、CD22、CD79a、CD79b、CD66d或其任意组合。优选地,所述初级信号传导结构域包含CD3ζ的信号传导结构域。更为优选地,所述初级信号传导结构域与SEQID NO:11、12或13所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。
在一些实施方案中,本公开的CAR还包含信号肽,所述信号肽选自以下蛋白的信号肽:CD8α、IgG1、GM-CSFRα、IgG4或其任意组合。优选地,所述信号肽包含CD8α或B2M的信号肽。更为优选地,所述信号肽与SEQ ID NO:14或15所示的氨基酸序列具有至少70%,优选至少80%,更优选至少90%、95%、97%或99%或100%的序列同一性。
在一些实施方案中,本公开的CAR还包含接头,其用于隔开任何本文中所述的结构域/区。例如,接头可位于信号肽与抗体之间、抗体的VH与VL之间、抗体与铰链区之间、铰链区与跨膜结构域之间、侧接共刺激结构域或在共刺激结构域的N-或C-区上、和/或在跨膜结构域与初级信号传导结构域之间。接头可以是长度为约6至约40个氨基酸、或长度为约6至约25个氨基酸的肽。
在一个实施方案中,本公开的工程化Th9细胞还包含至少一种MHC相关基因表达被抑制或沉默,例如使至少一种MHC基因的表达被抑制或沉默,或使与至少一种MHC基因相互作用或调控其表达的基因的表达被抑制或沉默。
在一个实施方案中,MHC相关基因表达被抑制或沉默是指使选自以下的一个或多个基因的表达被抑制或沉默:HLA-A、HLA-B、HLA-C、B2M、HLA-DPA、HLA-DQ、HLA-DRA、TAP1、TAP2、LMP2、LMP7、RFX5、RFXAP、RFXANK、CIITA或其任意组合,优选选自HLA-A、HLA-B、HLA-C、B2M、RFX5、RFXAP、RFXANK、CIITA或其任意组合。
在一个实施方案中,本公开的工程化免疫细胞还包含至少一种TCR/CD3基因的表达被抑制或沉默。
在一个实施方案中,使至少一种TCR/CD3基因表达被抑制或沉默是指使选自以下的一个或多个基因的表达被抑制或沉默:TRAC、TRBC、CD3γ、CD3δ、CD3ε、CD3ζ。
在一个实施方案中,除了MHC相关基因和任选的TCR/CD3基因,本公开的工程化Th9细胞还可以包含至少一种选自以下的基因的表达被抑制或沉默:CD52、GR、dCK和免疫检查点基因,如PD1、LAG3、TIM3、CTLA4、PPP2CA、PPP2CB、PTPN6、PTPN22、PDCD1、HAVCR2、BTLA、CD160、TIGIT、CD96、CRTAM、TNFRSF10B、TNFRSF10A、CASP8、CASP10、CASP3、CASP6、CASP7、FADD、FAS、TGFBRII、TGFRBRI、SMAD2、SMAD3、SMAD4、SMAD10、SKI、SKIL、TGIF1、IL10RA、IL10RB、HMOX2、IL6R、IL6ST、EIF2AK4、CSK、PAG1、SIT、FOXP3、PRDM1、BATF、GUCY1A2、GUCY1A3、GUCY1B2和GUCY1B3。
抑制基因表达或使基因沉默的方法是本领域技术人员熟知的,包括但不限于例如通过大范围核酸分子酶、锌指核酸分子酶、TALE核酸分子酶或CRISPR系统中的Cas酶介导DNA断裂、或通过反义寡核苷酸、RNAi、shRNA等技术使基因失活。
在一个实施方案中,本公开的工程化Th9细胞不与除T细胞、NK细胞之外的其他免疫细胞,例如巨噬细胞、树突细胞等组合使用。优选地,本公开的工程化Th9细胞不与任何其他免疫细胞组合使用。
在一个实施方案中,本公开的工程化的Th9细胞还表达一种或多种外源性的细胞因子,所述细胞因子选自IL-2、IL-7、IL-12、IL-15、IL-21、IL-17、IL-18、IL-23、TSLP、XCL1、XCL2、CXCL9、CXCL10、CXCL11、CXCL12、CX3CL1、CCL2、CCL3、CCL4、CCL5、CCL7、CCL8、CCL12、CCL13、CCL19、CCL21。优选地,所述细胞因子选自TSLP、IL7、XCL1和XCL2。更优选地,所述细胞因子是TSLP,或IL7和XCL1的组合,或IL7和XCL2的组合,或IL7、XCL1和XCL2的组合。
组合物
本公开还提供一种组合物,其包含本公开所述的工程化Th9细胞作为活性剂,和一种或多种药学上可接受的赋型剂。
如本文所用,术语“药学上可接受的赋型剂”是指在药理学和/或生理学上与受试者和活性成分相容(即,能够引发所需的治疗效果而不会引起任何不希望的局部或全身作用)的载体和/或赋形剂。药学上可接受的赋型剂的实例包括但不限于填充剂、粘合剂、崩解剂、包衣剂、吸附剂、抗粘附剂、助流剂、抗氧化剂、调味剂、着色剂、甜味剂、溶剂、共溶剂、缓冲剂、螯合剂、表面活性剂、稀释剂、润湿剂、防腐剂、乳化剂、包覆剂、等渗剂、吸收延迟剂、稳定剂和张力调节剂。本领域技术人员已知选择合适的赋型剂以制备本公开期望的药物组合物。用于本公开的药物组合物中的示例性赋型剂包括盐水、缓冲盐水、葡萄糖和水。通常,合适的赋形剂的选择尤其取决于所使用的活性剂、待治疗的疾病和药物组合物的期望剂型。
根据本公开的药物组合物可适用于多种途径施用。通常,通过胃肠外完成施用。胃肠外递送方法包括局部、动脉内、肌内、皮下、髓内、鞘内、心室内、静脉内、腹膜内、子宫内、阴道内、舌下或鼻内施用。
根据本公开的药物组合物还可以与一种或多种适用于治疗和/或预防待治疗疾病的其它药剂组合施用。适用于组合的药剂的优选实例包括已知的抗癌药物,比如顺铂、美登素衍生物、雷查霉素(rachelmycin)、卡里奇霉素(calicheamicin)、多西紫杉醇、依托泊苷、吉西他滨、异环磷酰胺、伊立替康、美法仑、米托蒽醌、sorfimer卟啉钠II(sorfimersodiumphotofrin II)、替莫唑胺、拓扑替康、葡萄糖醛酸曲美沙特(trimetreateglucuronate)、奥利斯他汀E(auristatin E)、长春新碱和阿霉素;肽细胞毒素,比如蓖麻毒素、白喉毒素、假单胞菌细菌外毒素A、DNA酶和RNA酶;放射性核素,比如碘131、铼186、铟111、铱90、铋210和213、锕225和砹213;前药,比如抗体定向的酶前药;免疫刺激剂,比如IL-2,趋化因子比如IL-8、血小板因子4、黑色素瘤生长刺激蛋白等;抗体或其片段,比如抗CD3抗体或其片段,补体活化剂,异种蛋白结构域,同种蛋白结构域,病毒/细菌蛋白结构域和病毒/细菌肽。
用途
本公开还提供上述工程化Th9细胞或药物组合物在制备治疗/预防/诊断癌症、感染或自身免疫性疾病药物中的用途。
在一个实施方案中,所述疾病是与Claudin18.2表达有关的癌症。例如,所述癌症包括但不限于:食管癌、胃肠癌、胰腺癌、甲状腺癌、结直肠癌、肾癌、肺癌(例如非小细胞肺癌)、肝癌、胃癌、胃食管交界处(GEJ)腺癌、头颈癌、膀胱癌、乳腺癌、子宫癌、宫颈癌、卵巢癌、前列腺癌、睾丸癌、生殖细胞癌、骨癌、皮肤癌、胸腺癌、胆管癌、胆囊癌、黑素瘤、间皮瘤、淋巴瘤、骨髓瘤(例如多发性骨髓瘤)、肉瘤、神经胶质母细胞瘤、白血病、畸胎瘤、成神经细胞瘤、神经胶质瘤、直肠癌、子宫内膜癌、肾上腺癌、脑癌、结肠癌、头颈癌、淋巴结癌、耳鼻喉(ENT)癌,优选选自胃癌、胃食管交界处(GEJ)腺癌、食管癌、胃肠癌、胰腺癌、肺癌等。
下面将参考附图并结合实施例来详细说明本公开。需要说明的是,本领域的技术人员应该理解本公开的附图及其实施例仅仅是为了举例,并不能对本公开构成任何限制。在不矛盾的情况下,本申请中的实施例及实施例中的特征可以相互组合。
附图说明
图1示出了各种CAR-T细胞中的CAR表达水平。
图2示出了各种CAR-T细胞的扩增水平。
图3示出了各种CAR-T细胞的LAG3表达水平。
图4示出了各种CAR-T细胞的IL9释放水平。
图5示出了各种CAR-T细胞对靶细胞的杀伤活性。
图6示出了经各种CAR-T细胞处理的胃癌小鼠的体重变化。
图7示出了经各种CAR-T细胞处理的胃癌小鼠的肿瘤负荷变化。
具体实施方式
实施例1.制备CAR-T细胞
1.1构建载体
构建MSCV-cCAR质粒,其包含编码以下蛋白的核酸序列:Claudin18.2-VHH(SEQ IDNO:4)、CD8α铰链区(SEQ ID NO:19)、CD8α跨膜区(SEQ ID NO:7)、41bb胞内域(SEQ ID NO:10)和CD3ζ胞内域(SEQ ID NO:13)。
在上述MSCV-cCAR质粒中进一步包含编码IL-7(SEQ ID NO:26)和XCL1(SEQ IDNO:27)的核酸序列,其通过T2A(SEQ ID NO:21)的编码序列连接,获得MSCV-71CAR质粒。
在上述MSCV-cCAR质粒中进一步包含通过T2A(SEQ ID NO:21)连接的TSLP(SEQ IDNO:22),获得MSCV-TSCAR质粒。
1.2制备CAR-T细胞
将PBMC用 CD4+T cell分离试剂盒(Miltenyi Biotec)分选后,获得初始CD4+T细胞。在含有10ng/ml IL-4、1ng/ml TGF-β1、10μg/ml anti-human IFNγ的X-VIVO15培养基中培养10天,获得Th9细胞。
将MSCV-cCAR质粒、MSCV-71CAR质粒和MSCV-TSCAR质粒包装入逆病毒后,分别转染激活的T细胞或Th9细胞,获得六种细胞:cCAR-T细胞、71CAR-T细胞、TSCAR-T细胞、cCAR-Th9细胞、71CAR-Th9细胞和TSCAR-Th9细胞。未转染病毒的T细胞或Th9细胞作为阴性对照(NT或NTh9)。
取2×105个CAR-T细胞,用Anti-Camelid VHH-iFluor 488(金斯瑞)作为流式检测抗体,通过流式细胞术检测CAR的表达水平,结果如图1所示。可以看出,各种CAR-T细胞上的CAR均可有效表达。
实施例2.CAR-T细胞的功能验证
此外,通过细胞计数检测CAR-T细胞的增殖能力,结果如图2所示。可以看出,CAR-Th9细胞的增殖能力均高于CAR-T细胞,其中,71CAR-Th9细胞的增殖能力最强,TSCAR-Th9和cCAR-Th9细胞次之。
通过流式细胞术检测LAG3的表达水平,从而评估细胞的耗竭状态,结果如图3所示。可以看出,与CAR-T细胞相比,CAR-Th9细胞的LAG3表达水平显著降低,表明CAR-Th9的耗竭水平更低,能够持续的时间更长。
在96孔圆底板中以2×105个细胞/100μl的浓度分别加入NT细胞和各种CAR-T细胞,然后在各孔中以1×104个细胞/100μl的浓度分别加入靶标NUGC4-Claudin18.2细胞(表达human Claudin18.2的NUGC4细胞)或非靶标NUGC4细胞。于37℃培养14h后,收集培养物上清液,并用Human IL-9DuoSet ELISA试剂盒(R&D)检测培养物上清液中IL-9的表达水平。结果如图4所示。可以看出,与CAR-T细胞相比,CAR-Th9细胞与靶标细胞共培养后释放的IL9水平显著升高,这更有助于招募体内其他免疫细胞。
以1×104个细胞/100μl/孔的浓度将靶细胞NUGC4-Claudin18.2-luci细胞铺入96孔板中,然后以20:1、10:1、5:1和1:1的效靶比将各CAR-T细胞和CAR-Th9细胞铺入到96孔板进行共培养,8小时后利用酶标仪测定荧光值。根据计算公式:(靶细胞荧光均值-样品荧光均值)/靶细胞荧光均值×100%,计算得到杀伤效率,结果如图5所示。可以看出,CAR-T细胞和CAR-Th9细胞的体外杀伤活性相当。
实施例3.CAR-T细胞的肿瘤抑制效果验证
在健康NPI小鼠的左前肢腋下部位,经皮下接种4×106个NUGC4-Claudin18.2胃癌细胞。将接种了胃癌细胞的小鼠随机分为5组,每组6只。待肿瘤体积生长至100mm3时,向各组小鼠经尾静脉注射PBS或1×106个71CAR-T细胞、TSCAR-T细胞、71CAR-Th9细胞以及TSCAR-Th9细胞。监测小鼠的体重和肿瘤体积变化,直至实验结束。
小鼠的体重变化如图6所示。可以看出,施用CAR-T细胞后,各组小鼠的体重与对照组相比没有显著差异,且在观察周期中,当小鼠肿瘤未超过1500mm3时,小鼠行动活泼,毛色正常,这表明,施用CAR-T细胞不会对小鼠有明显的毒副反应。
小鼠的肿瘤体积变化如图7所示。可以看出,71CAR-Th9细胞的抗肿瘤作用显著优于71CAR-T细胞,TSCAR-Th9细胞显著优于TSCAR-T细胞,表明与常规的T细胞相比,Th9细胞搭载的靶向Claudin18.2的CAR具有更好的肿瘤抑制效果。
需要说明的是,以上仅为本公开的优选实施例而已,并不用于限制本公开,对于本领域的技术人员来说,本公开可以有各种更改和变化。本领域技术人员理解的是,凡在本公开的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本公开的保护范围之内。
Claims (17)
1.一种工程化的Th9细胞,其表达特异性识别Claudin18.2的细胞表面分子。
2.根据权利要求2所述的Th9细胞,其还表达一种或多种外源性的细胞因子,所述细胞因子选自TSLP、IL7、XCL1和XCL2。
3.根据权利要求2所述的Th9细胞,其中所述细胞因子是TSLP。
4.根据权利要求2所述的Th9细胞,其中所述细胞因子是IL7和XCL1的组合,或IL7和XCL2的组合,或IL7、XCL1和XCL2的组合。
5.根据权利要求1所述的Th9细胞,其中所述细胞表面分子选自嵌合抗原受体、T细胞受体、T细胞融合蛋白或T细胞抗原耦合器。
6.根据权利要求1所述的Th9细胞,其中所述细胞表面分子包含结合Claudin18.2的抗体。
7.根据权利要求6所述的Th9细胞,其中所述抗体为完整抗体、Fab、Fab’、F(ab’)2、Fv片段、scFv抗体片段、线性抗体、sdAb或纳米抗体。
8.根据权利要求6所述的Th9细胞,其中所述抗体包含如SEQ ID NO:1、2、3所示的CDR-1、CDR-2和CDR-3。
9.根据权利要求6所述的Th9细胞,其中所述抗体与SEQ ID NO:4具有至少90%同一性。
10.根据权利要求1所述的Th9细胞,其中所述细胞表面分子是包含结合Claudin18.2的抗体的嵌合抗原受体,所述嵌合抗原受体还包含跨膜结构域和胞内结构域,其中所述胞内结构域包含共刺激结构域和/或初级信号传导结构域。
11.根据权利要求10所述的Th9细胞,其中所述共刺激结构域选自以下蛋白质的共刺激信号传导结构域:LTB、CD94、TLR1、TLR2、TLR3、TLR4、TLR5、TLR6、TLR7、TLR8、TLR9、TLR10、CARD11、CD2、CD7、CD8、CD18、CD27、CD28、CD30、CD40、CD54、CD83、CD134、CD137、CD270、CD272、CD276、CD278、CD357、DAP10、DAP12、LAT、NKG2C、SLP76、PD-1、LIGHT、TRIM、ZAP70或其任意组合。
12.根据权利要求10所述的Th9细胞,其中所述初级信号传导结构域选自以下蛋白的信号传导结构域:FcRγ、FcRβ、CD3γ、CD3δ、CD3ε、CD3ζ、CD22、CD79a、CD79b、CD66d或其任意组合。
13.根据权利要求10所述的Th9细胞,其中所述跨膜结构域选自以下蛋白质的跨膜结构域:TCRα链、TCRβ链、TCRγ链、TCRδ链、CD3ζ亚基、CD3ε亚基、CD3γ亚基、CD3δ亚基、CD45、CD4、CD5、CD8α、CD9、CD16、CD22、CD33、CD28、CD37、CD64、CD80、CD86、CD134、CD137、CD154或其任意组合。
14.根据权利要求1所述的Th9细胞,其中所述Th9细胞的至少一种MHC相关基因和/或至少一种TCR/CD3相关基因的表达被抑制或沉默。
15.根据权利要求14所述的Th9细胞,所述MHC相关基因选自HLA-A、HLA-B、HLA-C、B2M、HLA-DPA、HLA-DQ、HLA-DRA、TAP1、TAP2、LMP2、LMP7、RFX5、RFXAP、RFXANK、CIITA或其任意组合,优选HLA-A、HLA-B、HLA-C、B2M、RFX5、RFXAP、RFXANK、CIITA或其任意组合;所述TCR/CD3基因选自TRAC、TRBC、CD3γ、CD3δ、CD3ε、CD3ζ或其任意组合。
16.一种药物组合物,其中包含权利要求1-15任一项所述的Th9细胞和一种或多种药学上可接受的载体和/或赋型剂。
17.权利要求1-15任一项所述Th9细胞或权利要求16所述药物组合物在制备治疗/预防/诊断癌症的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211010624.2A CN117625543A (zh) | 2022-08-23 | 2022-08-23 | 工程化Th9细胞及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211010624.2A CN117625543A (zh) | 2022-08-23 | 2022-08-23 | 工程化Th9细胞及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117625543A true CN117625543A (zh) | 2024-03-01 |
Family
ID=90027543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211010624.2A Pending CN117625543A (zh) | 2022-08-23 | 2022-08-23 | 工程化Th9细胞及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117625543A (zh) |
-
2022
- 2022-08-23 CN CN202211010624.2A patent/CN117625543A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230399398A1 (en) | Cd7-targeting humanized antibody and use thereof | |
US11840575B2 (en) | Engineered immune cells targeting BCMA and their uses thereof | |
AU2019243448B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
US20240052029A1 (en) | Ror1-targeting antibody and use thereof | |
US20240082306A1 (en) | Novel chimeric antigen receptor and use thereof | |
EP4194472A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
EP4148125A1 (en) | Engineered immune cell for allotransplantation | |
WO2021249462A1 (zh) | 表达nk抑制性分子的工程化免疫细胞及其用途 | |
TW202208415A (zh) | Il-12裝甲的免疫細胞療法及其用途 | |
CN114616337A (zh) | 嵌合CD3融合蛋白与基于anti-CD3的双特异性T细胞激活元件的联合表达 | |
WO2022222910A1 (zh) | 靶向gprc5d的抗体及其用途 | |
WO2022111405A1 (zh) | 靶向Claudin18.2的抗体及其用途 | |
KR102393776B1 (ko) | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 | |
CN116063527A (zh) | 靶向间皮素的抗体及其用途 | |
CN117625543A (zh) | 工程化Th9细胞及其用途 | |
CN114015656A (zh) | 用于同种异体移植的工程化免疫细胞 | |
CN118126191A (zh) | 靶向TGF-β的嵌合抗原受体及其用途 | |
WO2023051414A1 (zh) | 靶向间皮素的抗体及其用途 | |
WO2024114767A1 (zh) | 耐免疫排斥的工程化细胞 | |
CN117430712A (zh) | 靶向cxcr6的嵌合抗原受体及其用途 | |
CN117247459A (zh) | 靶向cd69的工程化免疫细胞及其用途 | |
CN117645670A (zh) | 一种新型嵌合抗原受体及其用途 | |
CN117285647A (zh) | 靶向ccr8的嵌合抗原受体及其用途 | |
CN117362434A (zh) | 靶向b7-h3的抗体及其用途 | |
CN117004604A (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |